Ann: ATL1102 Clinical Trial Update, page-7

Correct
If the delay goes on for the next 3 weeks
Readout : end of Oct 2024
Results in Nov 2024
That tells me that the sp should be around $1.20 Going into a phase 3 . Molecule worth$$)
if the Tox and the DMD trial is a success

Now there is a good chance that the Per Board will take the Tox study and the DMD 6 month readout to the FDA to get urgent commercialisation .. considering the continuation of the 12 month dosing .FDA is keen to bring any drug to market that shows efficacy for this unmet need .
Now
This is only my opinion using announcements and valuations written by others re molecule worth in a phase 3 .